Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;86(3):882-889.
doi: 10.1007/s12020-024-03945-7. Epub 2024 Aug 14.

Finerenone and diabetic renal disease: a narrative review

Kirthika Venkatesan  1   2 , Mabel Mary James Cheryeth  3 , Anna Tintu Verghese  4   5 , Arpita Mariam Mathews  6 , Nikitha Ravisankar  5 , Parvathy Unnikrishnan  7 , Vishakh Prakash  8 , Hridya Harimohan  9 , Nisha Nigil Haroon  10 , Sandra James  11 , Somy Cherian  12   13
Affiliations
Review

Finerenone and diabetic renal disease: a narrative review

Kirthika Venkatesan et al. Endocrine. 2024 Dec.

Abstract

Overactivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and require dialysis. Finerenone is the first oral non-steroidal mineralocorticoid receptor (MR) antagonist used in patients with diabetic kidney disease and heart failure. Finerenone (also known as Kerendia) is more potent than spironolactone in reducing the progression of CKD and exerts its effect equally on the heart and kidneys, improving cardiovascular outcomes. Research demonstrates that finerenone improves proteinuria and glomerular filtration rate (GFR) if taken alone or in combination with sodium-glucose transporter 2 inhibitors (SGLT2i). Finerenone has been found to decrease mortality in patients with diabetic renal disease and improve quality of life. Its side effects, unlike those of spironolactone, do not include gynecomastia. However, it can result in hyperkalemia, which needs to be monitored. In this narrative review, we aim to investigate the mechanisms of action of finerenone and its implications in patients with type 2 diabetes.

Keywords: Finerenone; MeSH; Mineralocorticoid receptor antagonist; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards Conflict of interest The authors declare no competing interests.

References

    1. R. Agarwal, G. Filippatos, B. Pitt, S.D. Anker, P. Rossing, A. Joseph, P. Kolkhof, C. Nowack, M. Gebel, L.M. Ruilope, G.L. Bakris; FIDELIO-DKD and FIGARO-DKD investigators, Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: he FIDELITY pooled analysis. Eur. Heart J. 43(6), 474–484 (2022). https://doi.org/10.1093/eurheartj/ehab777 - DOI - PubMed
    1. Centers for Disease Control and Prevention (CDC). Diabetes and Chronic Kidney Disease. Retrieved from https://www.cdc.gov/diabetes/managing/diabetes-kidney-disease.html#:~:te... (2023)
    1. H. Li, W. Lu, A. Wang, H. Jiang, J. Lyu, Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J. Diab. Investig. 12(3), 346–356 (2021). https://doi.org/10.1111/jdi.13355 - DOI
    1. A. Makhlough, Z. Kashi, O. Akha, E. Zaboli, J. Yazdanicharati, Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan. Nephro-Urol. Monthly 6(1), e12148 (2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968951/
    1. D. Kawanami, Y. Takashi, Y. Muta, N. Oda, D. Nagata, H. Takahashi, M. Tanabe, Mineralocorticoid receptor antagonists in diabetic kidney disease. Front. Pharmacol. 12, 754239 (2021. https://www.frontiersin.org/articles/10.3389/fphar.2021.754239/full - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources